Skip to main content
single10MG

GHRP-2

10MG Protocol

GHRP-2 10MG

Injection Freq.

Inject once daily

Cycle Sched.

8–12 weeks; optional extension to 16 weeks with periodic breaks

Reconstitution

3.0 mL BAC water

Potent stimulation of endogenous pulsatile GH release
IGF-1 elevation reported with sustained administration
Used clinically as a diagnostic tool for GH deficiency evaluation
Anecdotal support for recovery, body composition, and sleep quality described
1

Reconstitution Requirements

  • 3.0 mL BAC water
StepWeek RangeDoseUnits
1Weeks 1–2100 mcg (0.1 mg)3
2Weeks 3–4150 mcg (0.15 mg)4.5
3Weeks 5–8200 mcg (0.2 mg)6
4Weeks 9–12250–300 mcg (0.25–0.3 mg)9

Inject once daily

8–12 weeks; optional extension to 16 weeks with periodic breaks

GHRP-2 is presented as a potent growth hormone–releasing peptide that works by acting as a ghrelin receptor (GHS-R1a) agonist. The protocol explains that it binds receptors in both the pituitary and hypothalamus, producing robust, pulsatile growth hormone release that resembles natural secretion patterns. It notes that even a single subcutaneous dose can raise GH several-fold above baseline and that sustained use over weeks can increase IGF-1. The page also highlights a practical limitation: with continuous daily dosing, the GH response can diminish (tachyphylaxis), which is why titration and planned breaks are commonly included. Mechanistically, the peptide is framed as stimulating endogenous GH rather than replacing it. The protocol also notes that, because it mimics ghrelin signaling, appetite effects can be prominent, and higher exposures may influence other hormones such as cortisol and prolactin. Overall, the mechanism is endocrine pulse amplification via ghrelin-receptor activation, moderated by desensitization dynamics.
Increased appetite (ghrelin-mimetic effect)
Transient flushing/warmth/tingling
Possible mild increases in cortisol and prolactin (higher doses)
Water retention or joint stiffness with prolonged high-dose use
Response attenuation (tachyphylaxis) with continuous daily dosing
  • Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
  • Add diluent slowly down the vial wall to minimize foaming
  • Gently swirl/roll until fully dissolved (do not shake)
  • Label vial with reconstitution date and concentration; protect from light
  • Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
  • Avoid repeated freeze–thaw cycles
  • Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
  • Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)